Reprocessing of Single-Use Devices in Turkey: Madde 17 Explained

1. Key takeaways

Reprocessing single-use devices is one of the areas where Turkish law redraws legal identity rather than merely imposing a technical procedure. The party that reprocesses steps into the shoes of the manufacturer, with every obligation that entails. The points below set out the dual source of the rules, the manufacturer fiction, the in-house carve-out and the amendment trail of the provision.

• The reprocessing (yeniden işleme) and reuse of single-use devices must comply at the same time with the guidelines published by TİTCK and with Madde 17 of the Regulation (paragraph 1 of Madde 17).
• A person who processes a single-use device into a reusable state is regarded in law as the manufacturer of that device and bears all manufacturer obligations under the Regulation, including the traceability obligations in Part Three (paragraph 2 of Madde 17).
• Paragraph 2 of the same article further provides that the reprocessor is regarded as a manufacturer within the legislative purpose of Article 6 of the Law on Product Safety and Technical Regulations.
• Paragraph 3 of Madde 17 leaves room for exceptions for in-house situations of healthcare institutions, to be regulated by the Kurum (the specific conditions follow the guidelines published by TİTCK; practical estimate).
• The current version of Madde 17 results from amendment by Resmî Gazete Sayı 31907 (2022-07-29), and the body text is annotated (Değişik:RG-29/7/2022-31907).

2. Legal basis

The table below consolidates the instruments cited in this article. Note that the parent provision and the amending instrument are listed separately, because the annotation in the consolidated text is the practical tool for tracking whether the provision has since been altered again.

3. Expert insights

Insight one: reprocessing is a redistribution of legal identity, not a process step. The decisive question is not the specifics of the cleaning, sterilisation or testing processes, but legal identity: once a person processes a device labelled for single use into a reusable state, that person moves from healthcare institution or service provider to manufacturer. The technical documentation, CE marking, UDI, registration and vigilance obligations all arrive with that change of status. Organisations that plan reprocessing around the technical protocol alone routinely underestimate the compliance surface they are acquiring, because the obligations are not proportional to the effort of the wash cycle but attach wholesale to the manufacturer role. In commercial terms this means that pricing a reprocessing service as a cleaning contract, without loading the cost of documentation, assessment and vigilance duties onto the fee, erodes the margin of the entire arrangement over time.

Insight two: the guideline and the Regulation stand in an AND relationship. Paragraph 1 of Madde 17 is worded as execution according to the guideline published by the Kurum and the article itself; the two cannot substitute for each other. Complying with the statutory text while ignoring the TİTCK guideline, or studying the guideline without returning to the text, does not constitute complete compliance. Audit findings in this area therefore tend to cite the missing half of the pair, and a submission or procedure that references only one source should be treated internally as incomplete even before any external reviewer says so.

Insight three: the 2022 amendment is a tightening worth attention. Madde 17 was amended barely one year after the Regulation was published, which shows that reprocessing is a focal point of Turkish regulatory adjustment. Any further change will likewise leave an annotation at the provision in the form (Değişik:RG-...), which offers enterprises a low-cost version-monitoring method: watch the annotations, not the whole text. A periodic scan of the amendment markers on the provisions a business relies on is a far cheaper control than re-reading the full Regulation each cycle. In a service model, the same scan should extend to the contracts: where the reprocessor holds the manufacturer role, any shift in the underlying provision changes the allocation of duties between the parties, and the agreement should say in advance which side absorbs the cost of adapting to such a shift.

4. Practical recommendations

• Where the business involves third-party reprocessing services, run an identity assessment before accepting the order: whether the party taking on the work is capable of discharging all manufacturer obligations.
• In-house reprocessing by healthcare institutions must rest on the specific basis in the TİTCK guideline, with the operating procedure and validation evidence fixed in writing.
• Establish a traceability mapping between reprocessing batches and the original manufacturer’s products, in answer to the traceability requirements of Part Three (UDI and registration).

5. Verification checklist

• □ The current TİTCK guideline on reprocessing has been obtained (and applied together with Madde 17).
• □ It has been confirmed that the reprocessor bears manufacturer obligations, and the corresponding capability assessment has been completed.
• □ UDI, registration and traceability records have been established for reprocessed devices (Part Three of the Regulation).
• □ In-house reprocessing by healthcare institutions rests on an exemption basis under paragraph 3 (following the TİTCK guideline; practical estimate).
• □ It has been checked that Madde 17 remains the current version as amended by Sayı 31907.

Regulatory information verified to 29 October 2026. The provisions listed in this article were checked against the original text on the Turkish legislative information system (MevzuatNo 38657); the specific exemption conditions for in-house reprocessing by healthcare institutions were not obtained from the guideline original, and are handled as practical estimates.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Turkish market. Our team manages TITCK approval applications and UTS registrations, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com